Dr. Peter Anthony Nasseff, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 401 Stageline Drive, Suite 7, Hudson, WI 54016 Phone: 715-531-6760 Fax: 715-531-6761 |
Michael J Moller, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 900 6th St N, 102, Hudson, WI 54016 Phone: 715-386-0856 Fax: 715-386-0948 |
Dr. Randi L Erickson, PSY D LP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2910 Enloe St, Hudson, WI 54016 Phone: 715-377-0000 Fax: 715-377-0000 |
Mrs. Kristine Hemauer, M.A., LSW Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2910 Enloe St, Suite 104, Hudson, WI 54016 Phone: 715-377-0000 Fax: 715-377-0010 |
News Archive
Northwestern Medicine researchers are co-investigators in a breakthrough clinical trial that found transplanted human islets prevent hypoglycemic events and provide excellent glycemic control for patients with Type 1 diabetes with severe hypoglycemia. The results of the multi-center, single arm, phase III study are published in Diabetes Care on Monday, April 18. The research was funded by National Institute of Health grants through the National Institute of Allergy and Infectious Diseases and the National Institute for Diabetes and Digestive and Kidney Disease.
Reallocation of treatment resources could substantially decrease the problem of unmet need for treatment of mental disorders among serious cases in developed and developing countries.
Scientists have come up with a new discovery that could transform our understanding of how childhood growth and development are measured – the DNA clock. The study, published in the Proceedings of the National Academy of Science, is the first paper to...
An international stroke study found that standard and intensive blood pressure treatments were equally effective in the emergency treatment of acute intracerebral hemorrhage, a type of stroke caused by bleeding into the brain.
ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.
› Verified 7 days ago